1. Inserm, U563, Centre de Physiopathologie de Toulouse Purpan, Département d'Oncogenèse, Signalisation et Innovation thérapeutique, and Université Toulouse III Paul-Sabatier, Toulouse, France;
2. Centre for Cell Signalling, Institute of Cancer, Queen Mary University of London, London, United Kingdom;
3. Inserm, U858, Institute of Molecular Medicine Rangueil, and Faculté des Sciences Pharmaceutiques, Toulouse, France; and
4. Inserm, U698, Hôpital Bichat, Paris, France